MeiraGTx Announces An Oral Presentation And Eight Posters At The European Society Of Gene And Cell Therapy 2023 Annual Congress
Portfolio Pulse from Benzinga Newsdesk
MeiraGTx Holdings plc (NASDAQ:MGTX), a clinical stage gene therapy company, announced that it will present eight posters and one oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress. The presentations will cover a range of topics including preclinical efficacy of gene therapy for ALS, results of a phase 1 study of gene therapy for radiation-induced xerostomia, and development of alternatives to Triton X-100 cell lysis for AAV2, AAV5 and AAV8 primary recovery.
October 24, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MeiraGTx's presentations at the ESGCT 2023 Annual Congress could potentially boost investor confidence in the company's gene therapy research and development efforts.
The company's presentations at a major conference could potentially increase its visibility among investors and industry peers, potentially leading to increased investor confidence and a positive impact on its stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100